索磷布韦联合维帕他韦治疗丙型肝炎肝硬化患者疗效及安全性分析*

doi:10.3969/j.issn.1672-5069.2023.04.021

摘要/Abstract

摘要： 目的分析应用索磷布韦(SOF)联合维帕他韦(VEL)治疗代偿期慢性丙型肝炎肝硬化(CHC-CLC)和失代偿期丙型肝炎肝硬化(CHC-DLC)患者的疗效及安全性,为临床决策提供参考依据。方法 2020年3月～2022年3月我院肝病科诊治的CHC-CLC患者36例和CHC-DLC 患者27例,所有患者接受SOF联合VEL治疗12 w,对于CHC-DLC患者,另联合利巴韦林治疗。分别记录治疗4 w时的早期病毒学应答率(EVR)、治疗结束时病毒学应答率(EOT)、停药后24周SVR(SVR24)和停药后48周SVR(SVR48)。结果 CHC-CLC患者食管胃静脉曲张、肝性脑病、腹水发生率和血清胆红素水平显著低于CHC-DLC患者,差异有统计学意义(P<0.05),而外周血WBC、Hb、PLT及血清Alb和PTA显著高于CHC-DLC患者,差异有统计学意义(P<0.05);在随访结束时,CHC-DLC患者死亡3例(11.1%);CHC-CLC患者EVR、EOT、SVR24和SVR48分别为94.4%、100.0%、100.0%和100.0%,优于CHC-DLC患者【分别为83.3%、100.0%、83.3%和75.0%(P<0.05)】; CHC-CLC患者血清ALT水平为32(18,40)U/L,外周血WBC计数为4.1(3. 2,7.7)×10⁹/L,血小板计数为104(90,381)×10⁹/L,与CHC-DLC患者【分别为55(35,62)U/L、3.0(2.7,5.0)×10⁹/L和72(54,115)×10⁹/L,P<0.05】比,差异显著;在服药期间,4例CHC-CLC和8例CHC-DLC患者发生不良反应,主要为腹胀、食欲不振、乏力、搏动性头痛和暂时性血压升高。结论应用SOF联合VEL的DAAs治疗方案治疗CHC-CLC或CHC-DLC患者均具有很好的疗效,且安全。

关键词: 失代偿期肝硬化, 丙型肝炎, 直接抗病毒药物, 索磷布韦, 维帕他韦, 治疗

Abstract: Objective The aim of this study was to investigate the efficacy and safety of sofosbuvir (SOF) and velpatasvir (VEL) plus or not plus ribavirin in the treatment of patients with chronic hepatitis C-related compensated liver cirrhosis (CHC-CLC) and decompensated liver cirrhosis (CHC-DLC). Methods 36 patients with CHC-CLC and 27 patients with CHC-DLC were enrolled in this study between March 2020 and March 2022, and all patients received SOF and VEL and the patients with CHC-DLC were added with ribavirin for 12 weeks. The patients were followed-up for 48 weeks. The early virological response rate (EVR), the end of treatment response (EOT), the sustained virological response at 24 weeks (SVR24) and the SVR at 48 weeks (SVR48) after the discontinuation of the regimen were recorded. Results The incidences of esophageal varices, hepatic encephalopathy, ascites and hyperbilibubinemia in patients with CHC-CLC were much lower than(P<0.05), while the peripheral white blood cell (WBC) counts, hemoglobin concentration, platelet counts, serum albumin levels and prothrombin time activity were significantly higher than in patients with CHC-DLC(P<0.05); at the end of 48 week follow-up, three patients (11.1%) with CHC-DLC died; the EVR, EOT, SVR24 and SVR48 in patients with CHC-CLC were 94.4%, 100.0%, 100.0% and 100.0%, superior to 83.3%, 100.0%, 83.3% and 75.0%(P<0.05) in patients with CHC-DLC; in patients with CHC-CLC, serum alanine aminotransaminase level was 32(18, 40)U/L, peripheral WBC count was 4.1(3. 2, 7.7)×10⁹/L, platelet count was 104(90, 381)×10⁹/L, all significantly different as compared to [55(35, 62)U/L, 3.0(2.7, 5.0)×10⁹/L and 72(54, 115)×10⁹/L, respectively, P<0.05] in patients with CHC-DLC; during the antiviral treatment period, the untoward reactions were found in 4 patients with CHC-CLC and in 8 patients with CHC-DLC, including abdominal distension, anorexia, fatigue, throbbing headache and transient hypertension, which didn't influence the treatment. Conclusion The oral administration of SOF and VEL plus or not plus ribavirin in treatment of patients with with CHC-CLC and CHC-DLC is efficacious and safety, which warrants further clinical investigations.

Key words: Liver cirrhosis, Hepatitis C, Direct acting antivirals, Sofosbuvir, Velpatasvir, Therapy

丁闪闪, 丁凯, 姜宁. 索磷布韦联合维帕他韦治疗丙型肝炎肝硬化患者疗效及安全性分析^*[J]. 实用肝脏病杂志, 2023, 26(4): 536-539.

Ding Shanshan, Ding Kai, Jiang Ning. Sofosbuvir/velpatasvir plus ribavirin for patients with compensated and decompensated hepatitis C liver cirrhosis[J]. Journal of Practical Hepatology, 2023, 26(4): 536-539.

参考文献

[1] Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology, 2006, 43(6):1303-1310.
[2] Qu LX, Shi Y, Chen KY, et al. The distribution of hepatitis C virus infection in Shanghai, China: a time-spatial study. BMC Infect Dis, 2021, 21(1):974.
[3] Du G, Li X, Musa TH, et al. The nationwide distribution and trends of hepatitis C virus genotypes in mainland China. J Med Virol, 2019, 91(3):401-410.
[4] Huang K, Chen J, Xu R, et al. Molecular evolution of hepatitis C virus in China: A nationwide study. Virology, 2018, 516:210-218.
[5] Qi M, Yang M, Xu L, et al. Complete genome analysis identifies recombinant events and positive selection sites of hepatitis C virus from mainland China during 2010-2019. Virus Res, 2021, 296:198354.
[6] Xu XW, Wu XX, Chen KD, et al. Patients with chronic hepatitis C receiving sofosbuvir and ribavirin-based treatment, with or without interferon in Zhejiang, China: An observational study. Medicine (Baltimore), 2018, 97(38):e12403.
[7] Li H, Xiong N, Li C, et al. Efficacy of ribavirin and interferon-α therapy for hospitalized patients with COVID-19: A multicenter, retrospective cohort study. Int J Infect Dis, 2021, 104:641-648.
[8] 张耀弟, 张月荣, 王慧, 等. 聚乙二醇干扰素α联合利巴韦林治疗丙型肝炎失败和复发患者的临床特征及直接抗病毒药物疗效观察. 临床肝胆病杂志, 2019, 35(11):2456-2460.
[9] Tahata Y, Sakamori R, Urabe A, et al. Liver fibrosis is associated with corrected QT prolongation during ledipasvir/sofosbuvir treatment for patients with chronic hepatitis C. Hepatol Commun, 2018, 2(8):884-892.
[10] Ogawa E, Furusyo N, Nakamuta M, et al. Glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection: Results from a multicenter, real-world cohort study. Hepatol Res, 2019, 49(6):617-626.
[11] 中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2019年版).实用肝脏病杂志, 2020, 23(1): S33-52.
[12] 中华预防医学会医院感染控制分会, 中华医学会感染病学分会, 中华预防医学会感染性疾病防控分会. 中国丙型病毒性肝炎医院感染防控指南(2021年版). 中国感染控制杂志,2021, 20(6):487-493.
[13] 汤汝佳, 张宁, 周霞, 等. 直接抗病毒药物治疗肝移植术后丙型肝炎病毒感染受者的临床研究.中华肝胆外科杂志, 2021, 27(5):339-343.
[14] 黄爱龙, 袁正宏, 南月敏, 等. 乙型肝炎临床治愈策略:直接抗病毒药物. 中华肝脏病杂志, 2020, 28(8):640-644.
[15] Liu CH, Chen CY, Su WW, et al. Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis. Clin Mol Hepatol, 2021, 27(4):575-588.
[16] Li C, Li X, Zhu X, et al. Pharmacokinetics, safety, and tolerability of ledipasvir/sofosbuvir and sofosbuvir/velpatasvir in healthy Chinese subjects. Clin Ther, 2020, 42(3):448-457.
[17] Buggisch P, Wursthorn K, Stoehr A, et al. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany. PLoS One, 2019, 14(4):e0214795.
[18] 魏来, 王琴. 直接抗病毒药物时代慢性丙型肝炎的治疗:不同方案选择的考虑. 中华传染病杂志, 2018,36(10):577-586.
[19] Nic An Riogh E, Swan D, McCombe G, et al. Integrating hepatitis C care for at-risk groups (HepLink): baseline data from a multicentre feasibility study in primary and community care. J Antimicrob Chemother, 2019,74(Suppl 5):v31-v38.
[20] Rockstroh JK, Yazdanpanah Y. HepCare Europe: a new user-friendly hepatitis C care service model. What have we learned? What are the remaining challenges? J Antimicrob Chemother, 2019,74(Suppl 5):v2-v4.
[21] Tahata Y, Hikita H, Mochida S, et al. Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study. J Gastroenterol, 2021, 56(1):67-77.
[22] Margusino-Framiñán L, Cid-Silva P, Giménez-Arufe V, et al. Influence of drug-drug interactions on effectiveness and safety of direct-acting antivirals against hepatitis C virus. Eur J Hosp Pharm, 2021, 28(1):16-21.
[23] Barror S, Avramovic G, Oprea C, et al. HepCare Europe: a service innovation project. HepCheck: enhancing HCV identification and linkage to care for vulnerable populations through intensified outreach screening. A prospective multisite feasibility study. J Antimicrob Chemother, 2019, 74(Suppl 5):v39-v46.

索磷布韦联合维帕他韦治疗丙型肝炎肝硬化患者疗效及安全性分析^*

Sofosbuvir/velpatasvir plus ribavirin for patients with compensated and decompensated hepatitis C liver cirrhosis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨凯, 张凯, 汪勇. 应用聚乙二醇干扰素α-2a联合利巴韦林治疗慢性丙型肝炎患者血清sVAP-1和SAA水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(4): 484-487.
[2]	王卓雅, 吴洋鹏, 黄益桃. 多烯磷脂酰胆碱联合脂必泰治疗非酒精性脂肪性肝病患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(4): 496-499.
[3]	甄永利, 张亚飞, 张振华. 自身免疫性肝病患者甲状腺功能变化及其对治疗应答的影响^*[J]. 实用肝脏病杂志, 2023, 26(4): 508-511.
[4]	唐新华, 唐慧京, 黄成军, 李观. 恩替卡韦治疗血清HBeAg阳性高病毒载量乙型肝炎病毒携带者合并肺结核患者预防抗痨治疗引起的药物性肝损伤效果研究^*[J]. 实用肝脏病杂志, 2023, 26(4): 516-519.
[5]	袁小兵, 陈慰慰, 刘小莉, 姜铭, 范向军. 根治性肝叶切除术治疗肝细胞癌患者外周血自然杀伤细胞活力变化及其临床意义探讨[J]. 实用肝脏病杂志, 2023, 26(4): 544-547.
[6]	朱加猛, 范丽琴, 尹力, 吴柏华. 腹腔镜手术治疗巨大肝血管瘤患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(4): 564-567.
[7]	黄昱, 王卓, 任承纲, 张耀, 刘杨旸, 樊华, 何梅峰. PTGD后不同时间行LC治疗急性结石性胆囊炎患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(4): 568-571.
[8]	曾林, 张勇, 罗九宝, 吉彩云, 丹娜. LC术后应用疏利通泄汤治疗慢性胆囊炎合并胆结石患者对胃肠功能的影响^*[J]. 实用肝脏病杂志, 2023, 26(4): 572-575.
[9]	刘泽军, 慕海峰, 陈升宝, 王春, 徐刚. LC联合LCBDE同步手术治疗胆囊结石合并胆总管结石患者临床疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(4): 576-579.
[10]	郑峰, 李彦荣, 罗卫军, 张晓超. 经胆囊后三角入路和经胆囊三角入路腹腔镜胆囊切除术治疗胆囊结石伴慢性胆囊炎患者疗效及对血清炎症因子的影响^*[J]. 实用肝脏病杂志, 2023, 26(4): 580-583.
[11]	周红飞, 陈钟, 顾宏, 沙德胜. 胆管空肠Roux-en-Y吻合联合皮下空肠盲袢埋藏术治疗肝胆管结石患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(4): 584-587.
[12]	张绍全, 林炳亮. 肠道菌群与肝硬化研究进展^*[J]. 实用肝脏病杂志, 2023, 26(3): 313-316.
[13]	张丹蕾, 徐静. 艾米替诺福韦治疗慢性乙型肝炎患者早期疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(3): 336-339.
[14]	郭晓玲, 张耀武, 李梦桃, 张辉. 恩替卡韦联合肝爽颗粒治疗慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(3): 340-343.
[15]	王云云, 吴万锋, 李黎. 直接抗病毒药物治疗基因1b型慢性丙型肝炎合并2型糖尿病患者疗效及对血糖控制的影响^*[J]. 实用肝脏病杂志, 2023, 26(3): 344-347.